A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial.
The suspension doesn’t appear to be related to the drug, tominersen, and no other trials of the investigational treatment were impacted—including an ongoing global Phase 3 study due to read out in 2022.
The trial was likely paused to allow the pharma to reduce the amount of time the intrathecal catheters used for sampling… Read more »
UNDERWRITERS AND PARTNERS
